IFNB1 and myeloid sarcoma: Altogether, the in vitro and in vivo findings indicate that, except for IFN-β, the various FDA-approved MS drugs described here have a clear effect on the transition from a pro-inflammatory into an anti-inflammatory microglia phenotype (Figure 1A).